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S_minary Early age at natural menopause or bilateral ovanrectomy substantially reduce a woman's lifetime
nsk of breast cancer. Reversible 'bilateral ovariectomy' can now in effect be achieved by 'high-dose'
luteinising hormone releasing hormone (LHRH) agonists (LHRHAs). The harmful effects of such medical
reversible bilateral ovariectomy, in particular the increased risks of coronary heart disease and osteoporosis,
can in all likelihood be obviated by 'low-dose' oestrogen replacement therapy (ERT), specifically 0.625mg of
conjugated equine oestrogens (CEE) for 21 days in each 28-day treatment cycle, and such ERT use will only
negate to a relatively small extent the beneficial effect of such bilateral ovariectomy on breast cancer risk. We
calculate that such an LHRHA plus low-dose ERT regimen given to a premenopausal woman for 10 years
will, in addition to being a most effective contraceptive, decrease her lifetime risk of breast cancer by more
than 50%. We caculate that such a 10-year regimen will also decrease her risk of ovarian cancer by two-
thirds. This regimen should leave endometrial cancer risk and bone metabolism unaltered, and may reduce the
nsk of heart disease. The addition of a 'low-dose' progestogen to the regimen for 12 days in each 28-day
treatment cycle would be beneficial to the endometrium, but it will adversely affect risk factors for heart
disease and it may significantly reduce the benefit of the regimen as regards breast cancer. A satisfactory
compromise may be to add a low-dose progestogen for 12 days at less frequent intervals. Another possibility
may be to deliver a progestogen solely to the endometrium with an intra-uterine device; the benefits of such a
regimen would be a significant reduction in the incidence of breast, ovarian and endometrial cancer.
Hormonal contraception with combination-type oral contra-
ceptives (COCs) is very effective and significantly reduces a
woman's risk both of ovarian cancer and of endometrial
cancer (Henderson et al., 1983; Pike, 1987), but causes no
change or possibly, under certain circumstances, even an
increase in the risk of breast cancer (McPherson & Drife,
1986; Editorial, 1986), and, particularly in older premeno-
pausal women, an increase in the risk of cardiovascular
disease (Stadel, 1981). This paper discusses the possibility of
designing an alternative hormonal contraceptive (based on
luteinising hormone releasing hormone (LHRH) agonists
(LHRHAs)) to provide a greater overall benefit than COCs,
and, in particular, to reduce the risk of breast cancer.
Epidemiological, clinical and laboratory studies of breast
cancer have provided both direct and indirect evidence that
ovarian hormones play a critical role in the aetiology of this
disease (Kelsey, 1979; Moore et al., 1983). There is strong
epidemiological evidence that a late menarche and an early
menopause both significantly reduce the risk of breast
cancer. Delaying menarche through dIiet and exercise has
been proposed as an achievable preventive strategy
(Bernstein et al., 1987), but it has not appeared possible to
exploit the preventive aspect of early menopause, even
though it is well-established that early bilateral ovariectomy
has a very substantial effect on breast cancer risk (e.g.
bilateral ovariectomy at age 30 is estimated to reduce the
lifetime risk of breast cancer by some 80%). LHRHAs can,
however, be given in high enough doses ('high-dose
LHRHA') to eliminate ovarian steroid production comple-
tely (Gudmundsson et al., 1986; McLachlan et al., 1986) and
this 'reversible bilateral ovariectomy' raises the possibility
that, if appropriate treatment of its side-effects can be
achieved, use of such compounds as a contraceptive in the
premenopausal period may achieve a major reduction in a
woman's lifetime risk of breast cancer.
Use of combination-type oral contraceptives (COCs)
reduce a woman's risk of ovarian cancer very significantly
(Henderson et al., 1983; Pike, 1987). This protection appears
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to be the direct consequence of the prevention by these
agents of ovulation (COCs may also be considered as
effectively inducing a 'reversible bilateral ovariectomy') and
the attendant rupture of the ovarian surface (Henderson et
al., 1982). High-dose LHRHAs also prevent ovulation, so
that use of these agents should achieve the same protection
against ovarian cancer as do COCs.
Early menopause and COCs also reduce the risk of
endometrial cancer (Elwood et al., 1977; Henderson et al.,
1983; Pike, 1987). This is almost certainly the result of the
associated endometrial atrophy, and since high-dose
LHRHAs also induce this atrophy, they too, if used alone,
should achieve a substantial reduction in endometrial cancer
risk.
Use of high-dose LHRHAs is. however, associated with
major harmful side effects directly due to the associated
hypo-oestrogenism (Gudmundsson et al., 1986; McLachlan
et al., 1986). High-dose LHRHAs cause hot flushes in the
majority of women, and the hypo-oestrogenism will induce
significant bone loss (Christiansen et al., 1981). Blood lipid
patterns are also likely to be altered with long-duration use
in ways known to be associated with increased cardiovascu-
lar disease; low-density lipoprotein cholesterol (LDLC) will
almost certainly be increased and the ratio of high-density
lipoprotein cholesterol (HDLC) to LDLC decreased (Wahl
et al., 1983; Lewis, 1987; Kannel & Gordon, 1987;
Thorogood et al., 1987; Mann et al., 1988); early menopause
is associated with a significantly increased risk of cardiovas-
cular disease (Rosenberg et al., 1981).
Experience with use of menopausal oestrogen replacement
therapy (ERT) shows, however, that these harmful side
effects of LHRHA use are likely, in their turn, to be
eliminated by 'low-dose' ERT (Henderson et al., 1988). The
addition of ERT to LHRHA will not affect the protective
effect of LHRHAs on ovarian cancer risk, and we argue
below that an LHRHA plus ERT regimen can be given in
such a way as to retain the major portion of the reduced
breast cancer risk, and at least not to increase endometrial
cancer risk. An LHRHA plus ERT regimen appears, there-
fore, to offer an alternative hormonal contraceptive with
some notable advantages over even low-dose COCs; there
are currently clear problems with its use (in particular,
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expense and mode of LHRHA delivery), but, given sufficient
stimulus, as we believe we provide here, these technical
problems will be solved (LHRH antagonists, although not
clinically useful at present in this context, may replace
LHRHAs as the drug of choice to suppress ovarian function
(Fraser & Baird, 1987)).
BEast, ovarian and endometrial cancer incidenc rates
For most cancers, the incidence, i.e. the probability of being
diagnosed with the specific cancer within a year, increases
rapidly from childhood to old age and the relationship
between incidence and age is such that a straight line is
obtained if we plot the logarithm of incidence against the
logarithm of age (Cook et al., 1969). Breast cancer incidence
does not fit this pattern. For breast cancer, when the
logarithm of incidence is plotted against the logarithm of
age, there is a steeply sloping line during the premenopausal
period and a line with a much shallower slope in the
postmenopausal period, with a gradual transition between
the two lines during the perimenopause (Figure 1). This
incidence curve suggests that the menopause protects women
against breast cancer, and this has been established directly
by epidemiological studies (Kelsey, 1979; Moore et al., 1983).
The age-incidence curves for ovarian and endometrial cancer
show a similar pattern; both show a distinct change in slope
around age 50 and early menopause has been shown to
protect against both of these cancers (Elwood et al., 1977;
Hildreth et al., 1981; Pike, 1987). Early artificial menopause
(bilateral ovariectomy) has been shown to provide at least
equally effective protection against breast cancer and against
endometrial cancer (Elwood et al., 1977; Kelsey, 1979).
Early menopause with no subsequent hormone replace-
ment therapy (HRT), either with oestrogen alone (oestrogen
replacement therapy, ERT) or with oestrogen in combination
with a progestogen (oestrogen-progestogen replacement
therapy, EPRT), advances the age at which the transition to
the post-menopausal slope begins for each of these three
cancers. This is illustrated for breast cancer in Figure 2,
where natural menopause at age 50 (the average age at
natural menopause) is contrasted with natural menopause at
age 45 and with artificial menopause at age 35: bilateral
ovariectomy at age 35 will reduce the lifetime risk of breast
cancer by more than 60%. Equally significant decreases in
risk of ovarian and endometrial cancer are obtained by such
early menopause. It appears likely that medical bilateral
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Figwe 2 Age-incidence curves of breast cancer for (working
from top curve down) women with natural menopause at age 50
and at age 45, and with a bilateral ovariectomy at age 35
respectively (with no HRT given to any group).
ovariectomy with a high-dose LHRHA with no subsequent
HRT would achieve major reductions in the risk of all three
cancers.
BEast ccer
Epidemiological studies of ERT and breast cancer risk which
have used population controls clearly show that an increase
in exposure to exogenous oestrogen (unopposed by a proges-
togen) causes an increase in breast cancer risk (Henderson et
al., 1988; Key & Pike, 1988a). These studies relate essentially
to ERT given as conjugated equine oestrogens (CEE) at
daily doses of between 0.625mg and 1.25mg (with the mean
dose roughly midway between these) for an average of
approximately 26 days per cycle. These studies show that 20
years of such ERT use produces an increase of approxim-
ately 75% in breast cancer risk (relative risk of 1.75). In
contrast, epidemiological studies which have used hospital
controls have found little evidence of an increase in breast
cancer risk from even extended use of ERT. For a number
of reasons we believe that the hospital-based studies are
incorrect (Henderson et al., 1988; Key & Pike, 1988a).
A conservative approach to assessing the effect of high-
dose LHRHA+ERT on breast cancer risk is to assume that
the population-control studies are correct, i.e. to assume that
ERT does cause an increase in breast cancer risk and that
the magnitude of the risk is as found in the population-
control studies.
To calculate the effect on breast cancer risk of a high-dose
LHRHA+ERT regimen we have assumed that the LHRHA
use will induce a medical menopause (bilateral ovariectomy)
and that the effect of the ERT is the same as that observed
in postmenopausal ERT users. (The actual calculations were
made using the mathematical model described in Pike et al.
(1983), details of which are given in the Appendix.)
Table I shows the predicted relative risks for breast cancer
of using various high-dose LHRHA regimens for 5, 10, or 15
years at premenopausal ages. Row (i) shows the effects of
such a medical bilateral ovariectomy with no HRT. This
regimen, taken for 15 years, is calculated to reduce lifetime
risk by 80%. Row (ii) shows the combined effects of high-
dose LHRHA plus 'high-dose' ERT, i.e. the ERT that
I
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Table I Predicted relative nrsk (%) of breast cancer in women using
a 'high-dose' LHRHA+ERT regimen
Duration of regimen (years)
Regimen3 5 10 15
LHRHA plus
(i) No ERT (or HRT) 62°o 3 2(r/Y
(ii) 'High-dose' ERT 73°0 530/ 370/
(iii) 'High-dose' ERTfor 21 days
per 28-day cyde 710O 49o0 330%
(iv) 'Low-dose' ERT 70° 47r 30°,/0
(v) 'Low-dose' ERTfor 21 days
per 28-day cycle 680, 450 280%
aCalculations based on using the regimen at any times after the
first full-term pregnancy assumed to take place at age 22, and before
age 40.
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Fgwe 3 Age-incidence curves of breast cancer. Normal=
natural menopause at age 50 with no HRT, contrasted with
'high-dose' LHRHA plus 0.625mg CEE per day for 21/28 days
from age 30 to 40 and then natural menopause at age 50 with no
HRT.
produced a relative risk of 1.75 for 20 years of use in post-
menopausal women. The predicted results of using contin-
uous high-dose LHRHA plus this ERT dose (mean 0.94mg
day-l of CEE) for 21 days per 28-day cycle rather than 26
are shown in row (iii). The predicted results from a
0.625mgday-1 CEE regimen for 26 days per cycle are given
in row (iv) of the table. Row (v) of the table shows the
predicted results from using this 'low-dose' ERT regimen for
21 days per 28-day cycle. This LHRHA plus low-dose ERT
regimen for 21 days per 28-day cycle is calculated to reduce
lifetime breast cancer risk by nearly a third if used for only 5
years, and by more than 70% if used for 15 years. The
calculated breast cancer incidence curve for a woman using
this latter regimen for 10 years between her 30th and 40th
birthday is shown in Figure 3.
Cancer of the ovary
In addition to early menopause, the other two risk factors
that have been consistently found in epidemiological studies
of ovarian cancer are parity and use of COCs (Hildreth et
al., 1981; Henderson et al., 1983; Pike, 1987). Ovarian cancer
risk decreases steadily with increasing parity and with
increasing duration of COC use. Incomplete pregnancies also
appear to provide protection and these risk factors can be
Table I1 Predicted relative risk (Os) of ovarian
cancer in women using a 'high-dose'
LHRHA+ERT regimen
Duration of regimen (years) Relative risk
5 59,
10 33°0
15 160o
very successfully modelled mathematically by assuming that
the age-incidence curve has the shallow post-menopausal
slope when a woman is not ovulating (Pike, 1987). High-
dose LHRHAs suppress ovulation, as do COCs and preg-
nancies, and it therefore appears extremely likely that use of
LHRHAs will protect against ovanan cancer to the same
extent as do COCs.
Table II shows the predicted relative risks for ovanran
cancer of using a high-dose LHRHA regimen for 5, 10 or 15
years at premenopausal ages. (The calculations were made
using the mathematical model described by Pike (1987);
details are given in the Appendix.) Use of ovulation sup-
pressing doses of LHRHAs for only 5 years is predicted to
reduce the lifetime nrsk of ovarian cancer by as much as
40%; use for 15 years should reduce the risk by more than
80%.
Eadoe rcancer
Epidemiological studies show that post-menopausal ERT
causes a very significant increase in endometrial cancer risk
(Key & Pike, 1988b). It is therefore a matter of concern that
premenopausal LHRHA plus even low-dose ERT for only
21 days per 28-day treatment cycle may actually increase
endometrial cancer risk. It appears, however, that this will
not be so. Calculations show that the observed relative nrsks
in epidemiological studies of CEE can be predicted on the
basis of the induced endometrial cell-division rates (Pike,
1987; Key & Pike, 1988b). It is therefore necessary to show
that such a regimen will not induce any additional
endometrial-cell division over that occurring in a normally
cycling woman.
Studies of endometrial-cell division rates during the men-
strual cycle show that maximal response is produced by the
oestrogen concentrations achieved during the early part of
the follicular phase of the cycle, and that further increases in
oestrogen concentration do not produce any further
endometrial-cell response. It is not known whether high-dose
CEE produces this maximal response, but consideration of
the plasma bioavailable oestradiol concentration associated
with high-dose CEE suggests that it may not. Furthermore,
epidemiological studies show that low-dose ERT increases
risk of endometrial cancer significantly less than high-dose
ERT (Key & Pike, 1988b), and that the increased risk from
ERT is roughly proportional to ERT dose. It is, therefore,
reasonable to conclude that low-dose ERT may have an
associated effective mitotic rate only half that attained
dunng the unopposed oestrogen (follicular) phase of the
menstrual cycle; if this dose is given for 21 days in each 28-
day cycle the associated cumulative effective mitotic rate will
be three quarters that of a normally cycling premenopausal
woman (half the daily rate but for 3 weeks in every 4). Even
if this is an underestimate, it is very unlikely that the total
mitotic rate during such an ERT regimen would be greater
than that obtaining during a normal menstrual cycle: this is
especially so if this regimen is supplemented with a progesto-
gen during certain cycles (see below).
To calculate the effect on endometrial cancer nrsk of an
LHRHA+ERT regimen we have assumed that LHRHA use
will induce a medical menopause (bilateral ovariectomy) and
that the effect of the ERT is the same as that observed in
post-menopausal ERT users. (The actual calculations were
made using the mathematical model described in Pike
(1987).)
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In the light of the above discussion, continuous LHRHA
plus 0.625mg CEE given for 21 days per 28-day cycle will
leave a woman's endometrial cancer risk unaltered, or
slightly reduced, i.e. will have no untoward effect on her risk
of endometrial cancer.
Bon meabotm
Long-term studies have established that following a bilateral
ovariectomy low-dose ERT, given as mestranol (24pg
day-') can completely prevent post-menopausal bone loss
(Lindsay et al., 1976). While studies of comparable duration
have yet to be conducted with low-dose CEE, 0.625mg CEE
daily is sufficient to prevent post-menopausal metacarpal
bone loss completely for at least 24 months (Lindsay et al.,
1984). Other critenra for measuring the effects of ERT on
bone loss, including laboratory studies of the calcium/
creatinine ratio and epidemiological studies of ERT and risk
of osteoporotic fractures, confirm that 0.625mg CEE daily is
an adequate dose for preventing bone loss in women lacking
ovarian steroid production (Paganini-Hill et al., 1981;
Lindsay et al., 1984). CEE 0.3mg daily, while better than
placebo, is associated with bone loss in some patients
(Lindsay et al., 1984), although this may be obviated by the
addition of calcium supplements to the 0.3mg CEE regimen
(Ettinger et al., 1987). No studies have been conducted with
doses of CEE between 0.3 and 0.625mg and the mechanism
of action of oestrogen on bone has yet to be determined. It
is, therefore, impossible to predict with certainty the effects
of 0.625mg CEE given for 21 days per 28-day cycle, but
negative effects on bone, if any, are likely to be small, and if
they do occur in a small minority of women they may be
avoidable with the addition of calcium supplements. Specific
long-term studies need to be conducted.
Heart dise
The majority of epidemiological evidence suggests that ERT
given to post-menopausal women will reduce risk of cardio-
vascular disease (Henderson et al., 1988). The exact degree
of protection is uncertain, but is probably substantial (about
a 50% reduction after 10 years of 0.625mg CEE daily)
(Henderson et al., 1988). The beneficial effects of oestrogen
on serum cholesterol (raised HDLC and lowered LDLC) are
well established and are the probable reason for this reduc-
tion in risk (Henderson et al., 1988). A post-menopausal
0.625mg CEE regimen for 25 days per month has been
found to increase HDLC by 13% and decrease LDLC by
16% (Barnes et al., 1985).
The results of cross-sectional epideniiological studies show
that HDLC does not change with age over the menopausal
age range (Lewis, 1978; Wahl et al., 1983; Kannel &
Gordon, 1987; Thorogood et al., 1987; Mann et al., 1988),
and is thus unlikely to be affected by the long-term cessation
of ovarian function. LDLC, in contrast, increases signifi-
cantly over the menopausal age range. The extent of the
LDLC increase that is due to the cessation of ovarian
function is difficult to estimate from such cross-sectional
data since menopausal status is so closely associated with
age, and there is good evidence that LDLC can increase with
age independent of a change in menstrual status. Wahl et al.
(1983) found that (untreated) post-menopausal women
showed an increase in LDLC of 36% compared to premeno-
pausal women, and when this increase is adjusted for the
increase due to age alone using the age-adjusted total
cholesterol differences between premenopausal and post-
menopausal women found by Baird et al. (1985), as a guide,
the LDLC increase is reduced to 18%.
The latter figures are directly applicable to a high-dose
LHRHA regimen. A high-dose LHRHA plus 25 days per
month of 0.625mg CEE is thus predicted to cause HDLC to
rise some 13% and to leave LDLC essentially unchanged.
This regimen is close to the proposed regimen of LHRHA
plus 21 days 0.625mg CEE per 28-day treatment cycle, and
the proposed regimen is thus unlikely to adversely affect
cardiovascular disease risk and may well be beneficial.
Specific long-term studies need to be conducted.
Another relevant comparison is with COC use. Levels of
LDLC are only marginally higher while levels of HDLC are
substantially higher in women taking ERT than in women
taking most COC preparations, and CEEs are less thrombo-
genic than the synthetic oestrogen contained in all currently
marketed COCs. One would thus expect, on this evidence,
that cardiovascular disease rnsk in women on an
LHRHA+low-dose ERT regimen would be reduced in com-
parison to women using COCs.
Discssion
We have argued above that an LHRHA plus low-dose ERT
regimen for 21 days in each 28-day cycle will reduce a
woman's risk of breast cancer and of ovarian cancer to a
very significant extent, and that this regimen will not have a
deleterious effect on either bone metabolism or cardiovascu-
lar disease. Our calculations suggest that such therapy will
not increase endometrial cancer risk compared to a woman
of comparable age taking no exogenous hormones, and it
may even slightly reduce the nrsk of this cancer.
An oestrogen-progestogen regimen (EPRT) has become a
widely recommended and prescribed alternative HRT. The
addition of a progestational agent to ERT will provide a
benefit to the endometrium more comparable to COCs, and
is likely to further improve bone metabolism (Lobo, 1987),
but it is likely to have a deleterious effect on heart disease
risk and may have a deleterious effect on breast cancer
(Henderson et al., 1988; Key & Pike, 1988a). Small studies of
different synthetic progestogens strongly suggest that they
have an effect opposite to that of oestrogens on lipoprotein
metabolism, and result in a substantial increase in LDLC
and a substantial decline in HDLC (Silverstolpe et al., 1979).
These progestogenic effects are dose-dependent and, at the
commonly prescribed approximately equivalent doses (King
& Whitehead, 1986), it appears that they negate, or even
reverse, the beneficial effects of ERT (Henderson et al.,
1988). The addition of a progestogen is therefore likely to be
detrimental to the heart disease situation. This does not
mean that an LHRHA+EPRT regimen will necessarily
increase a woman's risk of heart disease relative to her risk if
she used no hormonal regimen, only that her heart disease
risk will be higher with LHRHA+EPRT than with
LHRHA+ERT.
Another concern about adding a progestogen to ERT is
that of breast cancer. Maximum mitotic activity in breast
tissue occurs around day 25 of the menstrual cycle at the
time of maximum progesterone levels (Ferguson &
Anderson, 1981), suggesting that progestogens may be
important breast-cell mitogens. In sharp contrast to the
marked reduction in endometrial cancer risk with COC use,
there is no evidence of a reduced risk of breast cancer even
after long periods of COC use. There is, in fact, some
evidence that COC use at perimenopausal ages, and possibly
at young ages, may even increase breast cancer risk (Hender-
son et al., 1988). (The reason for this may be that exposure
to mitogenic hormones in a perimenopausal woman, and in
a frequently anovular young woman, is greater when she is
using COCs than when she is not using exogenous hor-
mones.) There is no evidence that adding a progestogen to
high-dose LHRHA+ERT will benefit the breast cancer situa-
tion, and the mitotic activity data suggest that it may well
have a significant deleterious effect.
In the context of post-menopausal ERT, we have argued
that if the addition of a progestogen has even a moderate
adverse effect on the heart disease component of the risk-
benefit equation, then its addition is ill-advised when con-
sidered in mortality or 'serious disease' terms (Henderson et
al., 1988). Endometrial cancer is a significant clinical concern146 M.C. PIKE et al.
with ERT use in post-menopausal women and will be so
with a high-dose LHRHA+ERT regimen; long-term use of
unopposed ERT is therefore likely to be considered clinically
unacceptable by some physicians even if the predicted level
ofrisk is comparable to that of a premenopausal woman of
similar age using no exogenous hormones. Some 'com-
promise' is therefore called for in which progestogens are
prescribed at the lowest dose for the shortest possible time to
achieve the desired histological changes in the endometrium.
Twelve days of progestogen therapy appears to be the
minimum duration necessary to control endometrial hyper-
plasia completely (Studd et al., 1980; Whitehead et al., 1983),
but there is evidence to suggest that such a regimen is not
required every cycle (Schiff et al., 1982); a small proportion
of women will develop hyperplasia if progestogens are not
given every cycle, but few will develop symptoms, and a 12-
day progestogen course every 3-4 cycles will likely eliminate
any hyperplasia that has developed (Schiff et al., 1982). Such
a regimen will not only benefit the endometrium but will
also reduce bone loss. There will be no modification of the
beneficial effect on ovarian risk. The cardiovascular situation
should remain satisfactory, and any negative effect on breast
cancer risk should be sufficiently small as to leave the
regimen with a substantial beneficial effect on breast cancer
risk.
If alternative progestogen regimens are found (e.g. possi-
bly progestogen patches, or micronised progesterone)
(Ottosson et al., 1985; Editorial, 1988; Henderson et al.,
1988) that do not adversely affect the beneficial effects of
unopposed oestrogen (ERT) on lipoprotein cholesterol, and
other possible risk factors (Lin et al., 1982; Makila et al.,
1982; Henderson et al., 1988), for cardiovascular disease,
then the critical unknown in the comparison of EPRT and
ERT will be the effect of progestogen on the risk of breast
cancer. Current research on the relation of medroxyproges-
terone acetate and low-dose COCs to breast cancer risk will,
hopefully, give us some further guidance on this vital issue.
Since the only reason for wanting to add a progestogen to
the proposed LHRHA+ERT regimen is to reduce
endometrial-cell proliferation, an alternative approach would
be to somehow deliver a progestogen solely to the endome-
trium, thus avoiding any further changes in cardiovascular
or breast cancer risk. The 'Progestasert' (Alza Corporation,
Palo Alto, CA) intra-uterine device does just this; this
progesterone-releasing device suppresses the proliferative
activity of the endometrium without apparently affecting
serum hormone levels (Hagenfeldt et al., 1977). Whether a
regimen of LHRHA+ERT plus a possibly modified
Progestasert-type device could be made clinically acceptable
and acceptable to women will need to be carefully evaluated:
the benefits of such a regimen would be a significant
reduction in the incidence of breast, ovarian and endometnral
cancer.
In the first instance, after the essential evaluation of effects
on lipid and bone metabolism and clinical acceptability are
carried out, the proposed high-dose LHRHA plus low-dose
ERT regimen might be offered to women at particularly high
risk of breast cancer, and possibly only after they have
completed their child-bearing. Although the beneficial effects
of this regimen in the perimenopausal years are likely to be
less than in the stnrctly premenopausal period, 15 years of
use starting at age 35 (assuming menopause at 50) is
predicted to reduce lifetime breast cancer risk to 49%
(compared to 28% in row (iv) of Table I), and if use started
at age 30 to 31%.
Appendix
Mathematical model of breast cancer
The calculations shown in Table I are based on the 'model'
of breast cancer incidence of Pike et al. (1983). In brief, the
incidence of breast cancer at age Ti I(T), can be written
I(T) =a[M(T)]4-5
where M( n is proportional to the sum of the average
'effective mitotic rates',m(t), of breast cells from birth to age
T, i.e. t taking all values from birth to age T This model
provides an excellent quantitative description of the age-
incidence curve and of the major known risk factors for
breast cancer, ifrnt) is defined as follows:
mrt)=0 from birth to menarche;
=1 from menarche (taken as occurrng at age 13) to
first full-term pregnancy (FFTP, taken as
occurring at age 22); 2.2 is added tom(t) for the
year in which FFTP occurs;
=0.7 from FFTP to age 40,
=0.105 after menopause (last menstrual period, taken
as occurring at age 50); andnmt) declines
linearly from 40 to menopause.
For the 'average' woman not using ERT, we have
M(50)=9+2.2+ 18 x 0.7+10 x(0.7+0.105)/2
=27.825
and
M(70) =27.825+20 x 0.105
=29.925.
The calculations for row (i) in Table I were made by
assuming that the average effective mitotic rate is reduced
from the premenopausal value of 0.7 to the post-menopausal
value of 0.105 during the time the high-dose LHRHA
regimen (with no ERT) is used.
In the framework of this model, the assumed relative risk
of 1.75 for 20 years of ERT use (considered to start at
menopause at age 50 and be continuous to age 70 when risk
is assessed) implies that
M(70, ERT for 20 years)=M*(70)=33.888
(calculated so that (M*(70)/29.925)4-5= 1.75). But
M$(70) =M(50) +20 xm$
where m* is proportional to the average effective mitotic rate
of breast cells on the ERT regimen. Thus
m* =(33.888-27.825)/20
=0.303
The calculations for row (ii) in Table I were made by
assuming that the average effective mitotic rate is reduced
from 0.7 to 0.303 during the time the high-dose
LHRHA+ERT regimen is used.
If such ERT is given for 21 days rather than the assumed
26 days per 28-day cycle, the associated effective mitotic rate
is predicted to change from 0.303 to 0.265. This is calculated
as follows:
0.303 =(26/28) x m++ (2/28) x 0.105
where m+ is the mitotic rate on those days ERT is taken,
0.105 is the normal post-menopausal rate and the ERT is
taken for 26 days per 28-day cycle. From this equation,
m+=0.318; and
0.265=(21/28) x m++ (7/28) x 0.105
The calculations for row (iii) in Table I were made by
assuming that the average effective mitotic rate is reduced
from 0.7 to 0.265 during the time the high-dose
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If ERT is given at a dose of 0.625mg CEE, 'low-dose'
ERT, for 26 days per 28-day cycle, the associated average
effective mitotic rate is predicted to change from 0.303 to
0.237. This is calculated as follows:
m+ =0.318=0.213+0.105
0.625mg CEE is two-thirds the dose of CEE associated with
m+, thus the effective mitotic rate, m-, while actually on
low-dose ERT, if proportional to ERT dose is
m =(2/3) x 0.213+0.105
=0.247
and the average effective mitotic rate over a 28-day cycle is
0.237=(26/28) x 0.247+(2/28) x 0.105.
The calculations for row (iv) in Table I were made by
assuming that the average effective mitotic rate is reduced
from 0.7 to 0.237 during the time the high-dose
LHRHA+low-dose ERT regimen is used.
If such low-dose ERT is given for 21 days rather than the
assumed 26 days per 28-day cycle, the associated average
effective mitotic rate is predicted to change to
0.212=(21/28) x m- +(7/28) x 0.105
where m- is the effective mitotic rate on those days that
low-dose ERT is taken, 0.105 is the normal post-menopausal
rate and the ERT is taken for 21 days per 28-day cycle. The
calculations for row (v) in Table I were made by assuming
that the average effective mitotic rate is reduced from 0.7 to
0.212 during the time the high-dose LHRHA+21-day low-
dose ERT regimen is used.
The relative risks shown in Table I apply specifically to
age 70 since the normal increase in M after age 50 is small
these relative risks essentially predict the situation for all
ages over 50; the predicted relative risks under age 50 are
less (protection greater) than the figures shown in Table I.
Mathematical model of ovarian cancer
The calculations shown in Table II are based on the 'model'
of ovarian cancer incidence of Pike (1987). In brief, the
incidence of ovarian cancer at age T, I(T), can be written
I(T)=a[M(T)]4
where M(T) is proportional to the sum of the average
'effective mitotic rates', m(t), of ovarian epithelial cells from
birth to age i i.e. t taking all values from birth to age T
This model provides an excellent quantitative description of
the age-incidence curve and of the major known risk factors
for ovarian cancer, if m(t) is defined as follows:
m(t)=0.09 before menarche (taken as occurring at age
13); after menopause (taken as occurring at
age 50); and for the periods of anovulation
associated with pregnancy and taking COCs;
=1 otherwise.
For an 'average' woman with three children we have
M(50)=50-13-3+0.09 x(13+3)
=35.44
and
M(70) =35.44+20 x 0.09
=37.24.
In the framework of this model,
M(70,LHRHA for D years)=37.24-D+0.09 x D
=37.24-0.91 x D.
The calculations in Table II were made on this basis.
The relative risks shown in Table HI apply specifically to
age 70, since the normal increase in M after age 50 is small
these relative risks essentially predict the situation for all
ages over 50, the predicted relative risks under age 50 are
less (protection greater) than the figures shown in Table H.
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